Which vaccines go off patent, and when?
3 blockbuster vaccines with about $16.4B in 2025 worldwide sales lose US exclusivity between 2025 and 2037, led by Prevnar 20 (Pfizer, $6.5B). The biggest single year is 2035, with $6.5B.
2025 worldwide sales of each drug, placed in the year its first US generic or biosimilar can launch. Select a year for every drug going off patent that year.
| Drug | Company | US LOE | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Gardasil | Merck | 2028 | $5.2B | Patent-expiry estimate | No US filing found | – |
| Shingrix | GSK | 2029 | ≈$4.8B | Patent-expiry estimate | No US filing found | – |
| Prevnar 20 | Pfizer | 2035 | $6.5B | Company guidance | No US filing found | – |
Sorted by the year US exclusivity ends. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Pfizer | Prevnar 20 | $6.5B | 10% |
| Merck | Gardasil | $5.2B | 8% |
| GSK | Shingrix | ≈$4.8B | 11% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.